JP2024525740A5 - - Google Patents
Info
- Publication number
- JP2024525740A5 JP2024525740A5 JP2024501799A JP2024501799A JP2024525740A5 JP 2024525740 A5 JP2024525740 A5 JP 2024525740A5 JP 2024501799 A JP2024501799 A JP 2024501799A JP 2024501799 A JP2024501799 A JP 2024501799A JP 2024525740 A5 JP2024525740 A5 JP 2024525740A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- compound according
- stereoisomer
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163222646P | 2021-07-16 | 2021-07-16 | |
| US63/222,646 | 2021-07-16 | ||
| PCT/US2022/073782 WO2023288305A1 (en) | 2021-07-16 | 2022-07-15 | Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024525740A JP2024525740A (ja) | 2024-07-12 |
| JP2024525740A5 true JP2024525740A5 (enExample) | 2025-07-23 |
Family
ID=84919760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024501799A Pending JP2024525740A (ja) | 2021-07-16 | 2022-07-15 | 小分子サイクリン依存性キナーゼ４／６（ｃｄｋ４／６）およびｉｋｚｆ２（ｈｅｌｉｏｓ）分解剤並びにその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240376096A1 (enExample) |
| EP (1) | EP4370126A4 (enExample) |
| JP (1) | JP2024525740A (enExample) |
| CN (1) | CN117396208A (enExample) |
| AU (1) | AU2022311961A1 (enExample) |
| CA (1) | CA3217661A1 (enExample) |
| WO (1) | WO2023288305A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4493554A1 (en) | 2022-03-17 | 2025-01-22 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118420612A (zh) * | 2023-02-01 | 2024-08-02 | 沈阳药科大学 | 一种基于cdk4/6抑制剂的靶向蛋白降解化合物及制备方法和用途 |
| WO2025245178A1 (en) * | 2024-05-21 | 2025-11-27 | Innovo Therapeutics, Inc. | Pak4, cstf2, or cstf2t protein degraders, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE314370T1 (de) | 2002-01-22 | 2006-01-15 | Warner Lambert Co | 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| WO2009014642A1 (en) * | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer |
| EA019094B1 (ru) | 2008-08-22 | 2014-01-30 | Новартис Аг | Пирролопиримидины и их применение |
| TW201014830A (en) | 2008-09-30 | 2010-04-16 | Theravance Inc | Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid |
| US20120115878A1 (en) | 2010-11-10 | 2012-05-10 | John Vincent Calienni | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| EP2755482B1 (en) | 2011-09-15 | 2016-06-01 | Merck Sharp & Dohme Corp. | Combination of mk-1775 and mk-8776 for treating cancer |
| AU2014220354B2 (en) | 2013-02-21 | 2018-02-01 | Pfizer Inc. | Solid forms of a selective CDK4/6 inhibitor |
| BR112017021283A2 (en) | 2015-04-16 | 2018-06-26 | Novartis Ag | ribocyclib tablet |
| AU2017254702B2 (en) * | 2016-04-22 | 2020-12-24 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use |
| KR20200086278A (ko) * | 2017-10-18 | 2020-07-16 | 노파르티스 아게 | 선택적 단백질 분해를 위한 조성물 및 방법 |
| US12226424B2 (en) * | 2018-04-09 | 2025-02-18 | Shanghaitech University | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates |
| BR112021015672A2 (pt) * | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
-
2022
- 2022-07-15 US US18/577,531 patent/US20240376096A1/en active Pending
- 2022-07-15 EP EP22843071.6A patent/EP4370126A4/en active Pending
- 2022-07-15 CN CN202280039096.5A patent/CN117396208A/zh active Pending
- 2022-07-15 CA CA3217661A patent/CA3217661A1/en active Pending
- 2022-07-15 JP JP2024501799A patent/JP2024525740A/ja active Pending
- 2022-07-15 AU AU2022311961A patent/AU2022311961A1/en active Pending
- 2022-07-15 WO PCT/US2022/073782 patent/WO2023288305A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2468021C2 (ru) | Гетероциклические соединения и их применение | |
| JP2020508302A5 (enExample) | ||
| JP2020517616A5 (enExample) | ||
| CA2922575C (en) | Pharmaceutical combinations for the treatment of cancer | |
| JP2022071077A5 (enExample) | ||
| EA016577B1 (ru) | Конъюгаты антитело-лекарство и их применение | |
| JP2015512943A5 (enExample) | ||
| JP2015512398A5 (enExample) | ||
| JP2008528671A5 (enExample) | ||
| US10759803B2 (en) | Asparagine endopeptidase (AEP) inhibitors for managing cancer and compositions related thereto | |
| US9801898B2 (en) | Glutamate dehydrogenase 1 inhibitors and methods of treating cancer | |
| US20160113925A1 (en) | Methods of treating cancer with a combination of glucose modulators and bcl-2 inhibitors | |
| KR20160110952A (ko) | 암을 치료하기 위한 신규한 방법 | |
| JP2012526766A5 (enExample) | ||
| JP2021530444A5 (enExample) | ||
| KR20070010125A (ko) | 인테그린과 선택적으로 결합하는 피페리디닐 표적화 화합물 | |
| JP2009503110A5 (enExample) | ||
| JP2024515809A5 (enExample) | ||
| US9266901B2 (en) | Compositions and methods for treating cancer | |
| JP2024125139A5 (enExample) | ||
| JP2012522842A5 (enExample) | ||
| JP2022539840A5 (enExample) | ||
| JP2009510165A5 (enExample) | ||
| CN105283456A (zh) | 5-溴-靛玉红 | |
| JP6450678B2 (ja) | 新規な化合物およびその使用 |